First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival

Share :
Published: 6 Dec 2015
Views: 2362
Rating:
Save
Dr Richard M. Stone - Dana-Farber Cancer Institute, Boston, USA

Dr Stone presents, at a press conference at ASH 2015, results from an international prospective randomised P-controlled double-blind trial.

The findings shows the multi-kinase inhibitor midostaurin prolongs survival, compared with placebo in combination with daunorubicin/cytarabine induction, high-dose C consolidation, and as maintenance therapy in newly diagnosed acute myeloid leukaemia patients with FLT3 Mutations.

Read the news story and watch the video interview for more information.